Tampa, FLNCT04104776Now EnrollingIRB Ready

Lymphoma Clinical Trial in Tampa, FL

Access cutting-edge lymphoma treatment through this phase 1/2 clinical trial at a research site in Tampa. Study-provided care at no cost to qualified participants.

Sponsored by Novartis Pharmaceuticals

Quick Self-Assessment

See if you qualify for this Tampa location

Preparing your pre-screening questions…

Expert Care in Tampa

Access lymphoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related lymphoma treatment provided free

Apply for This Tampa Location

Check if you qualify for this lymphoma clinical trial in Tampa, FL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Tampa

    Convenient for FL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Tampa site if eligible
  4. 4Begin participation

About This Lymphoma Study in Tampa

The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid tumors and lymphomas.

Sponsor: Novartis Pharmaceuticals

Who Can Participate

Inclusion Criteria

All Patients:
Adults aged ≥18 years with life expectancy ≥12 weeks
ECOG performance status 0-1
Adequate recovery from prior therapy-related toxicities (Grade ≤1, with exceptions)
Adequate bone marrow, renal, and hepatic function per protocol-defined thresholds
Willingness to provide tumor tissue and blood samples for biomarker analyses
Agreement to protocol-specified contraception requirements
Signed informed consent prior to study procedures Disease-Specific Inclusion Criteria: Phase 1 (Dose Escalation):
Histologically or cytologically confirmed locally advanced or metastatic solid tumors or lymphoma
Disease refractory to standard therapy or with no available effective standard treatment
For prostate cancer: castrate testosterone levels maintained throughout the study Phase 2 (Disease-Specific Cohorts):
M1: ARID1A mutant urothelial carcinoma or other ARID1A mutant solid tumors (with cohort specific prior therapy and RECIST 1.1 measurable disease requirements)
M2: ARID1A mutant ovarian clear cell carcinoma after prior platinum-based therapy (and bevacizumab unless contraindicated)
M3: ARID1A mutant recurrent/metastatic endometrial carcinoma after platinum therapy and appropriate immunotherapy
M4: Relapsed/refractory peripheral T cell lymphoma or diffuse large B cell lymphoma, transplant-ineligible, with measurable disease
M5: Relapsed/refractory pleural or peritoneal mesothelioma with documented BAP1 loss
M6: Metastatic castration-resistant prostate cancer (mCRPC) with documented progression after AR targeted therapy and taxane chemotherapy
M7: ARID1A wild type endometrial carcinoma (exploratory food-effect cohort)
M8: mCRPC treated with DZR123 in combination with enzalutamide, with cohort specific requirements for prior androgen receptor pathway inhibitor and chemotherapy exposure Key

Exclusion Criteria

All Patients: Medical Conditions:
Prior solid organ or allogeneic hematopoietic cell transplant
Active or untreated symptomatic CNS metastases (with limited exceptions)
Clinically significant cardiovascular disease, including uncontrolled arrhythmias or prolonged QTc
Active interstitial lung disease or pneumonitis
Uncontrolled infections or significant gastrointestinal disorders affecting absorption
Active HIV or hepatitis B/C infection
Concurrent malignancy requiring active treatment (with protocol-defined exceptions)
Pregnancy, breastfeeding, or inability to comply with protocol requirements Prior or Concomitant Therapy:
Recent anticancer therapy within protocol-defined washout periods
Prior EZH2 inhibitor treatment
Recent radiation or liver-directed therapies outside allowed windows
Use of strong CYP3A4/5 inhibitors or inducers Additional Cohort-Specific Exclusions:
M6 (mCRPC): Bone-only disease, unstable bone lesions, PSA-lowering herbal products, recent prohibited prostate cancer therapies
M8 (Combination): PSA-only disease, prior investigational androgen receptor pathway inhibitors, significant seizure risk, extensive prior bone marrow irradiation, active inflammatory gastrointestinal disease

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Tampa?

Yes, this clinical trial (NCT04104776) has an active research site in Tampa, FL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Lymphoma Treatment Options in Tampa, FL

If you're searching for lymphoma treatment options in Tampa, FL, this clinical trial (NCT04104776) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Tampa research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all lymphoma clinical trials near you to find additional studies recruiting in your area.

More Lymphoma Trials in Tampa, FL

See all lymphoma clinical trials recruiting in Tampa — not just this study.

Browse Lymphoma Trials in Tampa →

Browse More Trials by Condition

Lymphoma TrialsChronic Lymphocytic Leukemia TrialsDiffuse Large B-Cell Lymphoma TrialsFollicular Lymphoma TrialsMantle Cell Lymphoma TrialsWaldenstrom Macroglobulinemia TrialsPulmonary Hypertension TrialsPeripheral T-Cell Lymphoma TrialsAll Conditions →

Ready to Join in Tampa?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Tampa, FL